For Patients

Cancer Treatment Updates

Harnessing T-cell “stemness” could enhance cancer immunotherapy

March 28th, 2019

A new study provides insight into how cancer immunotherapy works and suggests ways to enhance the treatment’s effectiveness. The NCI-led study, published in Science, examined the effect of high potassium levels on T cells.

Read More

Szent-Györgyi Prize to honor NCI’s Steven A. Rosenberg

February 12th, 2019

The 2019 Szent-Györgyi Prize for Progress in Cancer Research will be awarded to NCI’s Steven A. Rosenberg, M.D., Ph.D., for his pioneering role in the development of immunotherapy.

Read More

AI approach outperformed human experts in identifying cervical precancer

January 10th, 2019

A research team from NIH and Global Good has developed a computer algorithm that can analyze digital images of the cervix and identify precancerous changes that require medical attention. The AI approach could be valuable in low-resource settings.

Read More

BRCA Exchange aggregates data on thousands of BRCA variants to inform understanding of cancer risk

January 9th, 2019

The BRCA Exchange, a global resource that includes data on thousands of inherited variants in the BRCA1/BRCA2 genes, is available to the public through a website and new smartphone app.

Read More

Study finds elevated risk of certain rare blood cancers after chemotherapy for most solid tumors

December 20th, 2018

In a new study, NIH investigators found that patients treated with chemotherapy for most solid tumors had an increased risk of tMDS/AML, a rare but often fatal blood cancer. The study, which used population-based data, was published in JAMA Oncology.

Read More

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

December 4th, 2018

A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.

Read More

Statement from NCI Director Dr. Norman E. Sharpless on the Death of Senator John McCain

August 27th, 2018

Senator John McCain, a long-time supporter of cancer research, passed away on August 25.

Read More

NCI-led research team develops predictor for immunotherapy response in melanoma

August 20th, 2018

In a new study, NCI-led researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a type of immunotherapy.

Read More

Rosenberg, NCI-supported researchers to receive 2018 Albany Prize

August 15th, 2018

NCI’s Steven A. Rosenberg, M.D., Ph.D., and two NCI-supported researchers have been named recipients of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for their pioneering immunotherapy research.

Read More

Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer

August 14th, 2018

Results from a randomized clinical trial show patients with HPV-positive oropharyngeal cancer treated with radiation and cetuximab had inferior survival compared to the current standard treatment with radiation and cisplatin. The trial’s goal was to find a less toxic treatment approach without compromising survival.

Read More

 1 2 3 >  Last ›